Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Gross profit margins are typically a sign of strong (or weak) pricing power and market share, and a 73% margin tells investors all they need to know. Hims & Hers is an industry leader, and its ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

It's common to get stuck on the latest headlines and fixate on what they mean for your portfolio. But regardless of what parts of the stock market rise and fall based on the latest news out ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...